• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全科医生对肺癌患者在人群水平上的分期和表现状态的评估:对预后和放疗需求分析的影响

General practitioner assessment of stage and performance status in lung cancer patients at a population level: implications for prognosis and radiotherapy needs analyses.

作者信息

Tyldesley S, Roques T W, Erridge S

机构信息

Department of Radiation Oncology, Vancouver Cancer Clinic, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.

出版信息

Lung Cancer. 2007 Sep;57(3):381-8. doi: 10.1016/j.lungcan.2007.03.024. Epub 2007 May 7.

DOI:10.1016/j.lungcan.2007.03.024
PMID:17485136
Abstract

BACKGROUND

Stage, weight loss, and performance status (PS) are important prognostic factors and eligibility factors for curative intent therapy for lung cancer patients. Details of stage, weight loss, and PS are often not collected until referral to a cancer specialist, and since not all patients are referred to cancer specialists these important variables are not well defined at a population level.

PATIENTS AND METHODS

Data on stage, weight loss, PS and referral pattern were requested from general practitioners (GPs) on all lung cancer patients diagnosed between May and June of 2002 in the province of British Columbia, Canada. Outcomes were analyzed in relation to survival and referral to a cancer centre.

RESULTS

395 patients were identified, and GP questionnaires were returned on 85% of the cases. Patients referred to a cancer centre shortly after diagnosis differed from those who were not referred. Patients who were not referred to a cancer centre consisted of two groups-patients with localized disease and good PS who tended to have a better survival than those who were referred, and patients with advanced disease and poor performance status who tended to have a worse survival than those who were referred. GP assessed stage and PS are prognostic factors for survival.

CONCLUSIONS

GP assessed stage and PS are prognostic factors for survival in lung cancer patients. The case mix of patients who are not referred to a cancer centre shortly after their diagnosis differs from those that are referred.

摘要

背景

分期、体重减轻和体能状态(PS)是肺癌患者根治性治疗的重要预后因素和入选标准。分期、体重减轻和PS的详细信息通常直到患者转诊至癌症专科医生时才会收集,而且由于并非所有患者都会转诊至癌症专科医生,这些重要变量在人群层面并未得到很好的界定。

患者与方法

向加拿大不列颠哥伦比亚省2002年5月至6月间确诊的所有肺癌患者的全科医生(GP)索要有关分期、体重减轻、PS及转诊模式的数据。分析了与生存及转诊至癌症中心相关的结果。

结果

共识别出395例患者,85%的病例返回了GP调查问卷。诊断后不久转诊至癌症中心的患者与未转诊患者有所不同。未转诊至癌症中心的患者包括两组——疾病局限且PS良好的患者,其生存往往优于转诊患者;以及疾病晚期且体能状态差的患者,其生存往往比转诊患者更差。GP评估的分期和PS是生存的预后因素。

结论

GP评估的分期和PS是肺癌患者生存的预后因素。诊断后不久未转诊至癌症中心的患者病例组合与转诊患者不同。

相似文献

1
General practitioner assessment of stage and performance status in lung cancer patients at a population level: implications for prognosis and radiotherapy needs analyses.全科医生对肺癌患者在人群水平上的分期和表现状态的评估:对预后和放疗需求分析的影响
Lung Cancer. 2007 Sep;57(3):381-8. doi: 10.1016/j.lungcan.2007.03.024. Epub 2007 May 7.
2
Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.对于接受二线化疗的复发性小细胞肺癌患者,体能状态和对一线化疗的敏感性是重要的预后因素。
Cancer. 2008 Nov 1;113(9):2518-23. doi: 10.1002/cncr.23871.
3
Recursive partitioning analysis of prognostic factors for survival in patients with advanced cancer.晚期癌症患者生存预后因素的递归划分分析
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1169-76. doi: 10.1016/j.ijrobp.2008.05.067. Epub 2008 Oct 19.
4
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.体能状态与减瘤性肾切除术:重新定义体能状态差患者的治疗策略
Cancer. 2008 Sep 15;113(6):1324-31. doi: 10.1002/cncr.23708.
5
Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer.小细胞肺癌预防性颅脑照射应用的评估
Cancer. 2009 Feb 15;115(4):842-50. doi: 10.1002/cncr.24105.
6
Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status.社会经济地位低下是Ⅰ期非小细胞肺癌患者生存的不良预后因素,且独立于手术治疗、种族和婚姻状况。
Cancer. 2008 May 1;112(9):2011-20. doi: 10.1002/cncr.23397.
7
Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival.直径3厘米及以下的I期非小细胞肺癌切除术后的预后因素:脏层胸膜侵犯不影响总生存率和无病生存率。
J Thorac Cardiovasc Surg. 2007 Sep;134(3):638-43. doi: 10.1016/j.jtcvs.2007.04.059.
8
[Lung cancer in women: clinical features and factors related to survival].[女性肺癌:临床特征及与生存相关的因素]
Tuberk Toraks. 2008;56(3):266-74.
9
Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer.肿瘤内血管侵犯对完全切除的病理I期非小细胞肺癌的预后影响
J Thorac Cardiovasc Surg. 2009 Feb;137(2):429-34. doi: 10.1016/j.jtcvs.2008.07.007. Epub 2008 Sep 14.
10
Prognostic factors in resected satellite-nodule T4 non-small cell lung cancer.切除卫星结节型T4非小细胞肺癌的预后因素
Ann Thorac Surg. 2007 Sep;84(3):934-8; discussion 939. doi: 10.1016/j.athoracsur.2007.04.097.

引用本文的文献

1
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.比较regorafenib、fruquintinib 和 TAS-102 在既往治疗的转移性结直肠癌患者中的疗效:五项临床试验的系统评价和网络荟萃分析。
Med Sci Monit. 2019 Dec 2;25:9179-9191. doi: 10.12659/MSM.918411.
2
Physician And Patient Barriers To Radiotherapy Service Access: Treatment Referral Implications.放疗服务获取中医生和患者面临的障碍:治疗转诊的影响
Cancer Manag Res. 2019 Oct 7;11:8829-8833. doi: 10.2147/CMAR.S168941. eCollection 2019.
3
Squamous cell carcinoma of the lung with simultaneous metastases to peritoneum and skeletal muscle.
肺的鳞状细胞癌伴同时性腹膜和骨骼肌转移。
Thorac Cancer. 2014 Jan;5(1):101-3. doi: 10.1111/1759-7714.12034. Epub 2014 Jan 2.
4
Barriers to accessing radiation therapy in Canada: a systematic review.加拿大获取放射治疗的障碍:系统评价。
Radiat Oncol. 2012 Oct 12;7:167. doi: 10.1186/1748-717X-7-167.